Introduction
Drug resistance is defined, in a clinical setting, as the point at which administration of the drug can no longer safely treat the disease state due to an induced change in the drug target or an inability of the drug to reach the target. With an anti-microbial agent, clinical resistance occurs when the minimum inhibitory concentration (MIC) of the drug, for a given microbial strain, exceeds that concentration of drug that can safely be administered. Resistance to a drug can arise by (1) mutation of the gene (or gene cluster); (2) by acquisition of extrachromosomal DNA, or a transposable plasmid, that carries the resistance gene or genes; (3) upregulation of the target; or (4) upregulation of an efflux mechanism.
We have recently suggested [1] an approach to combating drug resistance that involves the selection of resilient drug targets [2] that are evolutionally constrained and the development of robust drugs [3] that are less susceptible to the development of resistance. This Perspective will focus on selected, potentially resilient drug targets and describe efforts to produce drugs with various degrees of robustness for these targets in the disease areas of cancer, bacterial and viral infections. The highlighted drug targets include: BCR-ABL kinase; epithelial growth factor receptor (EGFR) kinase, and plateletderived growth factor (PDGFR) kinase in cancer; dihydrofolate reductase (DHFR) and DNA gyrase /topoisomerase IV in bacteria; and human immunodeficiency virus (HIV) protease and hepatitis C (NS3/4A) protease in viruses. As enzymes are evolutionally constrained to catalyze a chemical reaction, they have the potential of being resilient targets; however, properly identifying robust inhibitors remains a challenge for the field.
Drug resistance in enzyme targets in cancer
Drug resistance is now a widespread problem in cancer and is particularly problematic with kinase inhibitors, proteasome inhibitors [4, 5] and monoclonal antibodies [6] . Of these, kinase inhibitors comprise the largest class of anticancer agents where drug resistance has significantly limited treatment. In this Perspective the focus will be on the challenges of developing robust drugs to overcome resistance to inhibitors of the kinase domains of BCR-ABL, EGFR and PDGF. However, the success of imatinib was limited due to the selection of resistant mutants.
BCR-ABL inhibitors
Specifically, the Bcr-Abl variant with a T315I gatekeeper mutation in the ATP binding site was observed in 10-20% of CML patients after failure of imatinib [12, 13] . 
Drug resistance in enzyme targets in antibiotics
Antibacterial agents, like antineoplastic agents, target fast-growing proliferative cells.
While the targets differ, the occurrence of resistance is common to both classes of drugs and the development of robust drugs to overcome resistant variants is an active area of research. In this Perspective, we highlight efforts to develop robust drugs against dihydrofolate reductase (DHFR) and gyrase/topoisomerase IV.
Dihydrofolate reductase (DHFR) and trimethoprim (TMP) resistance companies [65, [68] [69] [70] , such as compound C, recently reported by Pfizer [69] .
Drug resistance in enzyme targets induced by antiviral agents
Much of anti-viral therapy is rightly focused on vaccine development. However, for a growing number of viruses, vaccines have remained elusive, or the virus evolves so quickly that their scope is limited. Although some successful antiviral agents target viral entry, several target the viral enzymes that include: proteases, transcriptases, integrases and neurominidases. As with all quickly evolving diseases there are challenges in developing inhibitors that are robust; one strategy is to target enzymes that are evolutionarily constrained. The viral proteases, which cleave a number of diverse substrates, represent an example of such a class, and to retain activity, the protease must cleave all the substrates.
Human immunodeficiency virus (HIV) protease inhibitors
HIV protease, which cleaves Gag and Gag-Pro-Pol polyproteins at ten varied sites necessary for the maturation of virus [71] , is a major therapeutic target for antiviral drugs. In the last twenty years, structure-based drug discovery efforts have led to the development of nine approved competitive active site protease inhibitors (PIs). These inhibitors are the most potent anti-HIV drugs and essential components of the highly active antiretroviral therapy (HAART) [72, 73] .
The development of drug resistance is a major reason for the failure of protease inhibitor therapy. The virus accumulates many mutations within the protease that prevent PIs from binding to the protease. More than half the residues within the protease mutate in different combinations and lead to drug resistance [74] [75] . Drug resistance is a subtle change in the balance of recognition events: the protease is still able to recognize and process the natural substrate sites in the Gag and Gag-Pro-Pol polyprotein, while no longer being effectively inhibited by the competitive inhibitor.
When resistance emerges, the interactions of the protease with an inhibitor are significantly altered while the interactions with a natural substrate are maintained.
Crystallographic studies of the wild-type protease bound to inhibitor molecules have shown that most of the PIs occupy a similar volume and contact similar residues within the active site of the protease. Drug resistance occurs where inhibitor atoms protrude beyond the substrate envelope and contact protease residues [76] . Thus, mutations at these sites would specifically impact inhibitor binding while maintaining substrate
cleavage. The observation that many of the drug resistant mutations in the active site do not contact the substrates led to the development of the substrate envelope hypothesis: inhibitors that fit well within the substrate envelope would be less susceptible to drug resistance as a mutation that affects inhibitor binding would simultaneously impact the recognition and processing of the majority of the substrates [76] . Of the currently prescribed inhibitors the most potent is darunivar (DRV) and although not designed with the substrate envelope constraint, DRV fits well within this volume [2, 77] . Darunavir, in combination with ritinovir, has a high genetic barrier to resistance [78] Developing robust HIV-1 PIs that avoid drug resistance has proven a challenging task, and the substrate envelope hypothesis provides an approach to solving this problem. A survey of five approved drugs using quantitative measures of the bound inhibitor outside the substrate envelope indicated that the exterior volume of the inhibitors correlated with the loss of affinity to mutant proteases [79] . The ability of the substrate envelope to correlate with resistance mutations prompted the prospective design of new inhibitors with a lower likelihood to develop resistance [3, [80] [81] [82] [83] . These studies assist in validating the use of the substrate envelope hypothesis [84] in structure-based drug design of novel HIV protease inhibitors and have yielded several leads for potential new drugs.
Hepatitis C NS/3A Protease Inhibitors
Drug resistance is also a major obstacle in the treatment of hepatitis C virus (HCV).
HCV infects an estimated 180 million people worldwide [85] . The essential HCV NS3/4A protease is an attractive therapeutic target responsible for cleaving at least four sites along the viral polyprotein. Many protease inhibitors are currently in clinical trials; however, multi-drug resistance is widespread and arises very quickly. A recent study [86] compares the co-crystal structures of substrate structures with co-crystal structures of inhibitor complexes and shows that, as in the case of HIV-1 protease [77, 79, [81] [82] [83] 87, 88] , primary drug resistance occurs in HCV NS3/4A where the inhibitors protrude away from the substrate envelope.
These findings suggest a general model for using the substrate envelope approach to predict patterns of drug resistance in other quickly evolving diseases. For drug resistance to occur, mutations must selectively weaken enzyme affinity for an inhibitor without significantly altering its activity. Mutations occur outside the substrate envelope to achieve this effect, as these molecular changes can selectively alter inhibitor binding without compromising enzyme activity. Whenever the interaction of a drug target with its biological substrates can be structurally characterized, we predict that drugs designed to fit within the substrate envelope will be less susceptible to resistance.
Structure-based design strategies can incorporate this as an added constraint to develop inhibitors that fit within the substrate envelope. As a general paradigm, design efforts incorporating the substrate envelope approach can lead to the development of more robust inhibitors that are less susceptible to resistance.
Conclusion
Drug resistance negatively impacts the lives of millions of patients and costs our society billions of dollars by limiting the longevity of many of our most potent drugs. Drug resistance develops so rapidly that new drugs quickly become less effective, as witnessed by the evolution of resistance to existing anti-cancer and antimicrobial agents (antibiotics, antivirals, antifungals and antiprotozoals). A recent survey of European intensive care doctors indicated that "50% have treated at least one patient with a gram-negative pathogen that was totally or almost totally resistant to all antibiotics during the previous six months." [89] Drug resistance research has been very much a disease specific endeavor, which has limited intellectual progress and breakthroughs. However, as shown in this perspective, we have highlighted many parallels among quickly evolving diseases, such as cancer and infectious disease.
A drug target is likely to be resilient to resistance if it cannot easily tolerate change and maintain function. Many drug targets are enzymes. As these enzymes perform highly constrained and critical chemical reactions, they may represent resilient targets that are less susceptible to drug resistance. However, disrupting the therapeutic target activity is necessary but not sufficient for developing a drug that avoids resistance.
A robust inhibitor is one that successfully inhibits a resilient target, and one that does 
